Choice of Endpoints (Cont.)

2/7/01


Click here to start


Table of Contents

PPT Slide

PPT Slide

Choice of Endpoints (Cont.)

HIV RNA Endpoints

Cross-Sectional vs. Failure Over Time

Time to Failure vs. Cumulative Proportion

PPT Slide

PPT Slide

Purely Virologic vs. Composite

Issues in Definition of:

Clinical Beliefs Underlying the Appropriate Use of Each Endpoint

Types of Study Endpoint in HIV Disease Studies

Composite Endpoints

Example

Example Continued

ACTG 359:Proportion vs. Change

ACTG 359: Proportion Below Detection

ACTG 359: Proportion Below Detection

ACTG 359: Proportion Below Detection

ACTG 359: Mean HIV-1 RNA Change from Baseline

Data Completeness

Primary Efficacy Comparison

Secondary Efficacy Analysis: RNA Change

ACTG 364

ACTG 364

ACTG 364

Loss to Follow-Up

PPT Slide

PPT Slide

PPT Slide

ACTG 398

ACTG 398 Continued

ACTG 398

ACTG 398 Continued

ACTG 398 Continued

ACTG 398 Continued

Analysis of Quantitative Endpoints

PPT Slide

PPT Slide

PPT Slide

Author: bohlin